A Multi-Arm Phase I Study of the PI3K/mTOR Inhibitors PF-04691502 and Gedatolisib (PF-05212384) plus Irinotecan or the MEK Inhibitor PD-0325901 in Advanced Cancer (Q47130538)

From Wikidata

Jump to navigation Jump to search

scientific article published on 24 October 2017

Language	Label	Description	Also known as
English	A Multi-Arm Phase I Study of the PI3K/mTOR Inhibitors PF-04691502 and Gedatolisib (PF-05212384) plus Irinotecan or the MEK Inhibitor PD-0325901 in Advanced Cancer	scientific article published on 24 October 2017

Statements

scholarly article

1 reference

Europe PubMed Central

PMC publication ID

8 January 2018

http://europepmc.org/abstract/PMC/5700209

A Multi-Arm Phase I Study of the PI3K/mTOR Inhibitors PF-04691502 and Gedatolisib (PF-05212384) plus Irinotecan or the MEK Inhibitor PD-0325901 in Advanced Cancer (English)

1 reference

Europe PubMed Central

PMC publication ID

8 January 2018

http://europepmc.org/abstract/PMC/5700209

1 reference

based on heuristic

inferred from title

Josep Tabernero Caturla

15

object named as

Josep Tabernero

1 reference

Europe PubMed Central

PMC publication ID

8 January 2018

author name string

Zev A Wainberg

1

1 reference

Europe PubMed Central

PMC publication ID

8 January 2018

http://europepmc.org/abstract/PMC/5700209

Maria Alsina

2

1 reference

Europe PubMed Central

PMC publication ID

8 January 2018

http://europepmc.org/abstract/PMC/5700209

Heloisa P Soares

3

1 reference

Europe PubMed Central

PMC publication ID

8 January 2018

http://europepmc.org/abstract/PMC/5700209

Irene Braña

4

1 reference

Europe PubMed Central

PMC publication ID

8 January 2018

http://europepmc.org/abstract/PMC/5700209

Carolyn D Britten

5

1 reference

Europe PubMed Central

PMC publication ID

8 January 2018

http://europepmc.org/abstract/PMC/5700209

Gianluca Del Conte

6

1 reference

Europe PubMed Central

PMC publication ID

8 January 2018

http://europepmc.org/abstract/PMC/5700209

Patrick Ezeh

7

1 reference

Europe PubMed Central

PMC publication ID

8 January 2018

http://europepmc.org/abstract/PMC/5700209

Brett Houk

8

1 reference

Europe PubMed Central

PMC publication ID

8 January 2018

http://europepmc.org/abstract/PMC/5700209

Kenneth A Kern

9

1 reference

Europe PubMed Central

PMC publication ID

8 January 2018

http://europepmc.org/abstract/PMC/5700209

Stephen Leong

10

1 reference

Europe PubMed Central

PMC publication ID

8 January 2018

http://europepmc.org/abstract/PMC/5700209

Nuzhat Pathan

11

1 reference

Europe PubMed Central

PMC publication ID

8 January 2018

http://europepmc.org/abstract/PMC/5700209

Kristen J Pierce

12

1 reference

Europe PubMed Central

PMC publication ID

8 January 2018

http://europepmc.org/abstract/PMC/5700209

Lillian L Siu

13

1 reference

Europe PubMed Central

PMC publication ID

8 January 2018

http://europepmc.org/abstract/PMC/5700209

Jennifer Vermette

14

1 reference

Europe PubMed Central

PMC publication ID

8 January 2018

http://europepmc.org/abstract/PMC/5700209

publication date

24 October 2017

1 reference

Europe PubMed Central

PMC publication ID

8 January 2018

http://europepmc.org/abstract/PMC/5700209

Targeted oncology

1 reference

Europe PubMed Central

PMC publication ID

8 January 2018

http://europepmc.org/abstract/PMC/5700209

12

1 reference

Europe PubMed Central

PMC publication ID

8 January 2018

http://europepmc.org/abstract/PMC/5700209

6

1 reference

Europe PubMed Central

PMC publication ID

8 January 2018

http://europepmc.org/abstract/PMC/5700209

775-785

1 reference

Europe PubMed Central

PMC publication ID

8 January 2018

http://europepmc.org/abstract/PMC/5700209

copyright license

Creative Commons Attribution-NonCommercial 4.0 International

24 October 2017

1 reference

April 2022 Public Data File from Crossref

copyright status

0 references

A Phase Ib Study of the Dual PI3K/mTOR Inhibitor Dactolisib (BEZ235) Combined with Everolimus in Patients with Advanced Solid Malignancies

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5700209

23 May 2018

A phase Ib dose-escalation study of the MEK inhibitor trametinib in combination with the PI3K/mTOR inhibitor GSK2126458 in patients with advanced solid tumors.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5700209

23 May 2018

A randomized phase II non-comparative study of PF-04691502 and gedatolisib (PF-05212384) in patients with recurrent endometrial cancer

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5700209

23 May 2018

MEK and PI3K inhibition in solid tumors: rationale and evidence to date

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5700209

23 May 2018

MEK Inhibitor PD-0325901 Overcomes Resistance to PI3K/mTOR Inhibitor PF-5212384 and Potentiates Antitumor Effects in Human Head and Neck Squamous Cell Carcinoma

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5700209

23 May 2018

First-in-Human Study of PF-05212384 (PKI-587), a Small-Molecule, Intravenous, Dual Inhibitor of PI3K and mTOR in Patients with Advanced Cancer.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5700209

23 May 2018

A phase Ib dose-escalation study of the oral pan-PI3K inhibitor buparlisib (BKM120) in combination with the oral MEK1/2 inhibitor trametinib (GSK1120212) in patients with selected advanced solid tumors

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5700209

23 May 2018

Dual pharmacological targeting of the MAP kinase and PI3K/mTOR pathway in preclinical models of colorectal cancer

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5700209

23 May 2018

Phase I dose-escalation and -expansion study of buparlisib (BKM120), an oral pan-Class I PI3K inhibitor, in patients with advanced solid tumors

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5700209

23 May 2018

Assessing PIK3CA and PTEN in early-phase trials with PI3K/AKT/mTOR inhibitors

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5700209

23 May 2018

PI3K and MEK inhibitor combinations: examining the evidence in selected tumor types

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5700209

23 May 2018

Development of PI3K inhibitors: lessons learned from early clinical trials

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5700209

23 May 2018

Clinical development of phosphatidylinositol 3-kinase inhibitors for cancer treatment

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5700209

23 May 2018

PIK3CA mutation H1047R is associated with response to PI3K/AKT/mTOR signaling pathway inhibitors in early-phase clinical trials

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5700209

23 May 2018

Combination of a MEK inhibitor at sub-MTD with a PI3K/mTOR inhibitor significantly suppresses growth of lung adenocarcinoma tumors in Kras(G12D-LSL) mice

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5700209

23 May 2018

PF-04691502, a potent and selective oral inhibitor of PI3K and mTOR kinases with antitumor activity

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5700209

23 May 2018

The Ras-ERK and PI3K-mTOR pathways: cross-talk and compensation

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5700209

23 May 2018

Cetuximab plus irinotecan in pretreated metastatic colorectal cancer patients: the ELSIE study

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5700209

23 May 2018

Antitumor efficacy of PKI-587, a highly potent dual PI3K/mTOR kinase inhibitor

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5700209

23 May 2018

Detection of KRAS and BRAF mutations in colorectal carcinoma roles for high-sensitivity locked nucleic acid-PCR sequencing and broad-spectrum mass spectrometry genotyping

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5700209

23 May 2018

A phase II study of PD-0325901, an oral MEK inhibitor, in previously treated patients with advanced non-small cell lung cancer

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5700209

23 May 2018

The PI3K pathway as drug target in human cancer

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5700209

23 May 2018

Status of PI3K inhibition and biomarker development in cancer therapeutics

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5700209

23 May 2018

Targeting the Raf-MEK-ERK mitogen-activated protein kinase cascade for the treatment of cancer

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5700209

23 May 2018

Multicenter phase II and translational study of cetuximab in metastatic colorectal carcinoma refractory to irinotecan, oxaliplatin, and fluoropyrimidines

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5700209

23 May 2018

Molecular profiling of patients with colorectal cancer and matched targeted therapy in phase I clinical trials.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5700209

23 May 2018

Inhibition of the PI3K/AKT/mTOR Pathway in Solid Tumors.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5700209

15 August 2018

Phase I study of PF-04691502, a small-molecule, oral, dual inhibitor of PI3K and mTOR, in patients with advanced cancer.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5700209

15 August 2018

Phase I pharmacokinetic and pharmacodynamic study of the oral MAPK/ERK kinase inhibitor PD-0325901 in patients with advanced cancers

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5700209

15 August 2018

Phase I Safety, Pharmacokinetic, and Pharmacodynamic Study of SAR245409 (XL765), a Novel, Orally Administered PI3K/mTOR Inhibitor in Patients with Advanced Solid Tumors

1 reference

https://api.crossref.org/works/10.1007%2FS11523-017-0530-5

21 January 2018

Randomized phase II trial of cetuximab, bevacizumab, and irinotecan compared with cetuximab and bevacizumab alone in irinotecan-refractory colorectal cancer: the BOND-2 study

1 reference

https://pubmed.ncbi.nlm.nih.gov/29067643

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Identifiers

10.1007/S11523-017-0530-5

1 reference

Europe PubMed Central

PMC publication ID

8 January 2018

http://europepmc.org/abstract/PMC/5700209

PMC publication ID

1 reference

Europe PubMed Central

PMC publication ID

8 January 2018

http://europepmc.org/abstract/PMC/5700209

PubMed publication ID

1 reference

Europe PubMed Central

PMC publication ID

8 January 2018

http://europepmc.org/abstract/PMC/5700209

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q47130538&oldid=2208401629"